The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells

The irreversible ERBB1/2/4 inhibitor neratinib has been shown to rapidly down-regulate the expression of ERBB1/2/4 as well as the levels of c-MET, PDGFRα and mutant RAS proteins via autophagic degradation. Neratinib interacted in an additive to synergistic fashion with the approved PARP1 inhibitor n...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Booth, Laurence, Roberts, Jane L., Samuel, Peter, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Poklepovic, Andrew, Dent, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927661/
https://ncbi.nlm.nih.gov/pubmed/29405820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1436024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados